Aminopyrimidines useful as inhibitors of protein kinases

ABSTRACT

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.12/791,976, filed Jun. 2, 2010, which is a continuation application ofInternational Patent Application No. PCT/US2008/056423, filed on Mar.10, 2008, which in turn claims the benefit under 35 U.S.C. §119 of U.S.Provisional Patent Application Nos. 60/906,086, filed on Mar. 9, 2007and 60/953,020, filed on Jul. 31, 2007.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to compounds useful as inhibitors ofprotein kinases. The invention also provides pharmaceutically acceptablecompositions comprising the compounds of the invention and methods ofusing the compositions in the treatment of various disorders. Theinvention also provides processes for preparing the compounds of theinvention.

BACKGROUND OF THE INVENTION

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinasecomprised of α and β isoforms that are each encoded by distinct genes[Coghlan et al., Chemistry & Biology 2000, 7, 793-803; and Kim andKimmel, Curr. Opinion Genetics Dev., 2000 10, 508-514]. Protein kinases,particularly GSK-3, have been implicated in various diseases, disorders,and conditions including Diabetes, Alzheimer's, Huntington's,Amyotrophic Lateral Sclerosis, Parkinson's, Bipolar disorder,Schizophrenia, Cerebral stroke, Chemotherapeutic-dependentleukocytopenia and Cardiac Hypertrophy. [PCT Application Nos.: WO99/65897 and WO 00/38675; Haq et al., J. Cell Biol. 2000, 151, 117-130;Hirotani et al, Circulation Research 101, 2007, pp. 1164-1174].

Inhibiting GSK-3 is the desired approach for treating these diseases,disorders, and conditions. In cardiac hypertrophy, active GSK-3 may beimportant for inhibiting hypertrophy. However, blocking GSK-3 appears tobe important for protecting against apoptosis in hypertrophied cardiacmyoctyes. [Haq et al., J. Cell Biol. 2000, 151, 117-130; Hirotani et al,Circulation Research 101, 2007, pp. 1164-1174].

GSK-3 regulates multiple downstream effectors associated with a varietyof signaling pathways. These proteins include glycogen synthase, whichis the rate limiting enzyme necessary for glycogen synthesis, themicrotubule associated protein Tau, the gene transcription factorβ-catenin, the translation initiation factor e1F2B, as well as ATPcitrate lyase, axin, heat shock factor-1, c-Jun, c-myc, c-myb, CREB, andCEPBα. These diverse protein targets implicate GSK-3 in many aspects ofcellular metabolism, proliferation, differentiation, and development.

In a GSK-3 mediated pathway that is relevant for the treatment of typeII diabetes, insulin-induced signaling leads to cellular glucose uptakeand glycogen synthesis. Along this pathway, GSK-3 is a negativeregulator of the insulin-induced signal. Normally, the presence ofinsulin causes inhibition of GSK-3 mediated phosphorylation anddeactivation of glycogen synthase. The inhibition of GSK-3 leads toincreased glycogen synthesis and glucose uptake [Klein et al., PNAS1996, 93, 8455-8459; Cross et al., Biochem. J. 1994, 303, 21-26); Cohen,Biochem. Soc. Trans. 1993, 21, 555-567; and Massillon et al., Biochem J.1994, 299, 123-128]. However, in a diabetic patient, where the insulinresponse is impaired, glycogen synthesis and glucose uptake fail toincrease despite the presence of relatively high blood levels ofinsulin. This leads to abnormally high blood levels of glucose withacute and long-term effects that may ultimately result in cardiovasculardisease, renal failure and blindness. In such patients, the normalinsulin-induced inhibition of GSK-3 fails to occur. It has also beenreported that in patients with type II diabetes, GSK-3 is overexpressed[see, PCT Application: WO 00/38675]. Therapeutic inhibitors of GSK-3 aretherefore potentially useful for treating diabetic patients sufferingfrom an impaired response to insulin.

GSK-3 activity is associated with Alzheimer's disease. The hallmarks ofthis disease are the extracellular plaques formed by aggregatedβ-amyloid peptides and the formation of intracellular neurofibrillarytangles via the tau protein.

It has been shown that GSK-3 inhibition reduces amyloid-β peptides in ananimal model of Alzheimer's disease. See pages 435, 438. Phiel et. al.,Nature 423, 435-439 (2003). Mice over-expressing amyloid precursorprotein (APP) treated with lithium (a GSK-3α inhibitor) over athree-week period showed over a 50% decrease in amyloid-β peptide tissuelevels.

The neurofibrillary tangles contain hyperphosphorylated Tau protein, inwhich Tau is phosphorylated on abnormal sites. GSK-3 is known tophosphorylate these abnormal sites in cell and animal models.Conditional transgenic mice that over-express GSK-3 develop aspects ofAD including tau hyperphosphorylation, neuronal apoptosis and spatiallearning deficit. Turning off GSK-3 in these mice restores normalbehavior, reduces Tau hyperphosphorylation and neuronal apoptosis.(Engel T et al., J Neuro Sci, 2006, 26, 5083-5090 and Lucas et al, EMBOJ, 2001, 20, 27-39) Inhibitors of GSK-3 have also been shown to preventhyperphosphorylation of Tau in cells [Lovestone et al., Current Biology1994, 4, 1077-86; and Brownlees et al., Neuroreport 1997, 8, 3251-55].

GSK-3 as a target for psychosis and mood disorders, such asschizophrenia and bipolar disease, respectively, have been reported inthe literature. AKT haplotype deficiency was identified in a subset ofschizophrenic patients which correlated with increased GSK-3 activity. Asingle allele knockout of GSK-3β resulted in attenuated hyperactivity inresponse to amphetamine in a behavior model of mania.

Several antipsychotic drugs and mood stabilizers used to treat bothschizophrenic and bipolar patients have been shown to inhibit GSK-3(Emamian et al, Nat Genet, 2004, 36, 131-137; Obrien et al, J Neurosci,2004, 24, 6791-6798; Beaulieu et al, PNAS, 2004, 101, 5099-5104; Li etal Int J Neuropsychopharmacol, 2006, pp 1-13; Gould T D, Expert OpinTher Targets, 2006, 10, 377-392). Furthermore, a recent patent, US2004/0039007 describes GSK-3 inhibitors that show anti-schizophrenic andanxiolytic effects in relevant mouse behavior models.

GSK-3 activity is associated with stroke. Wang et al. showed that IGF-1(insulin growth factor-1), a known GSK-3 inhibitor, reduced infarct sizein rat brains after transient middle cerebral artery occlusion (MCAO), amodel for stroke in rats. [Wang et al., Brain Res 2000, 859, 381-5;Sasaki et al., Neurol Res 2001, 23, 588-92; Hashimoto et al., J. Biol.Chem 2002, 277, 32985-32991]. US 2004/0039007 describes the effect ofGSK-3 inhibitors in MCAO, a stroke model in rats. These GSK-3 inhibitorssignificantly reduced striatal ischemic damage and reduced edemaformation in rats. Additionally, the rats “demonstrated markedimprovement in neurological function over the time course of theexperiment.”

For all the above reasons, there is a great need to develop compoundsuseful as inhibitors of protein kinases. In particular, it would bedesirable to develop compounds that are useful as inhibitors of GSK-3,particularly given the inadequate treatments currently available for themajority of the disorders implicated in their activation.

SUMMARY OF THE INVENTION

This invention provides compounds and pharmaceutically acceptablecompositions thereof that are useful as inhibitors of GSK-3 proteinkinases.

These compounds are represented by formula I:

or a pharmaceutically acceptable salt thereof, wherein the variables areas defined herein.

These compounds have surprising selectivity in blocking the tyrosineautophosphorylation form of the GSK-3 enzyme over the serine/threoninekinase form. These compounds are also surprisingly effective inincreasing axonal and dendritic branching in neuronal cells, which isuseful in the treatment of degenerative conditions such as stroke,Alzheimer's Disease, Parkinson's Disease, Huntington's Disease,Amyotrophic Lateral Sclerosis (ALS) Multiple Sclerosis (MS), Spinal CordInjury, Traumatic Brain Injury, Charcot-Marie-Tooth, Leukocytopenia,Diabetes, Diabetic Neuropathy, and Osteoporosis.

These compounds are also effective as chemomodulators of repair,regeneration, and cellular differentiation.

The present invention also provides processes for preparing thesecompounds, compositions, pharmaceutical compositions, and methods ofusing such compounds and compositions for inhibiting protein kinases.These compounds are particularly useful as GSK-3 inhibitors.

These compounds and pharmaceutically acceptable compositions thereof arealso useful for treating or preventing a variety of diseases, disordersor conditions, including, but not limited to, an autoimmune,inflammatory, proliferative, or hyperproliferative disease, aneurodegenerative disease, or an immunologically-mediated disease.

The compounds provided by this invention are useful for inhibitingkinases in vitro, in vivo, and ex vivo. These compounds also useful forthe study of kinases in biological and pathological phenomena; the studyof intracellular signal transduction pathways mediated by such kinases;and the comparative evaluation of new kinase inhibitors.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides compounds of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

Ht is

-   wherein any substitutable carbon on Ht is independently and    optionally substituted with —R¹⁰;-   Ring D is a 3-10 membered cycloaliphatic or heterocyclyl;    -   wherein said heterocyclyl contains 1-2 heteroatoms selected from        O, N, or S; and wherein the cycloaliphatic or heterocyclyl is        independently and optionally substituted with 1-5-R⁵; Ring D is        bonded to the pyrimidine via a carbon atom;-   Z¹ is N, CH, or CR¹⁰;-   R^(X) is H, halo, or C₁₋₆alkyl, wherein the alkyl is independently    and optionally substituted with 1-5 groups selected from halo, —CN,    and —OR;-   R^(Y) is H, halo, C₁₋₆alkyl, or a 5-6 membered heterocyclyl ring    containing 1-2 heteroatoms selected from O, N, or S;    -   wherein said R^(Y) is independently and optionally substituted        with 1-4 halo, CN, OR, or C₁₋₆alkyl;-   each R¹⁰ is independently selected from haloC₁₋₆alkyl, C₁₋₆ alkyl,    halo, OR, C(═O)R, CO₂R, COCOR, NO₂, CN, S(O)R, SO₂R, SR, N(R⁴)₂,    CON(R⁴)₂, SO₂N(R⁴)₂, OC(═O)R, N(R⁴)COR, N(R⁴)CO₂R;-   each R⁴ is independently selected from H, C₁₋₆alkyl, or    haloC₁₋₆alkyl;-   each R⁵ is independently selected from halo, haloC₁₋₆alkyl, or    C₁₋₆alkyl; and-   each R is independently selected from H, C₁₋₆alkyl, or    haloC₁₋₆alkyl.

One aspect of this invention provides compounds wherein Ht is

In some embodiments, R¹⁰ is halo. In other embodiments, R¹⁰ is fluoro.In some embodiments, R¹⁰ is H or fluoro. In some embodiments, R¹⁰ is H.In some embodiments, Z¹ is CR¹⁰. In other embodiments, Z¹ is N.

Another embodiment provides compounds wherein R^(X) is H or C₁₋₆ alkyl.In some embodiments, R^(X) is H or C₁₋₄ alkyl. In some embodiments, thealkyl is methyl, ethyl, cyclopropyl, or isopropyl. In some embodiments,the alkyl is methyl. In some embodiments, the alkyl is independently andoptionally substituted with 1-5 halo. In some embodiments, halo isfluoro. In some embodiments, R^(X) is C₁₋₆ alkyl. In other embodiments,R^(X) is H.

Another embodiment provides compounds wherein R^(Y) is halo or C₁₋₆alkyl. In some embodiments, R^(Y) is methyl. In some embodiments, R^(y)is H, chloro, methyl, 4-methyl piperazinyl, N-morphilinyl, or—C(CH₃)₂OH.

In some embodiments, R^(X) is H or methyl and R^(y) is methyl. In otherembodiments, R^(X) is H and R^(Y) is methyl. In yet other embodiments,R^(X) is methyl and R^(Y) is methyl.

Another embodiment provides compounds wherein R^(Y) is a 5-6 memberedheterocyclyl containing 1-2 heteroatoms selected from O, N, or S. Insome embodiments, R^(Y) is a 6-membered heterocyclyl containing 1-2heteroatoms selected from O or N. In some embodiments, the heterocyclylis morpholinyl, piperidinyl, or piperazinyl.

Another embodiment provides compounds wherein Ring D is a 5-10 memberedcycloaliphatic or a 5-10 membered heterocyclyl where said heterocyclylcontains 1-2 heteroatoms selected from O, N, or S. In some embodiments,Ring D is 3-6 membered cycloaliphatic. In other embodiments, Ring D is5-7 membered cycloaliphatic. In yet other embodiments, Ring D iscyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, oradamantly. In some embodiments, Ring D is cyclohexyl.

In some embodiments, Ring D is a 5-8 membered monocyclic or 8-10membered bicyclic cycloaliphatic or heterocyclyl.

According to another embodiment, Ring D is a 5-7 membered heterocyclylcontaining 1 heteroatom. In some embodiments, Ring D is a 6-memberedheterocyclyl containing one oxygen atom (tetrahydropyran).

In yet another embodiments, Ring D is cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, 4,4-difluoro-cyclohexyl, cycloheptyl,adamantly, or tetrahydro-2H-pyran-4-yl.

According to another embodiment, R⁵ is halo or C₁₋₆alkyl.

In some embodiments, Ring D is optionally substituted with methyl orhalo. In some embodiments, halo is fluoro.

In some embodiments, Z¹ is N, R¹⁰ is F, and Ring D is a 5-7 memberedcycloalkyl monocyclic ring.

In some embodiments, R^(x) is H or C₁₋₆alkyl, R^(y) is H or C₁₋₆alkyl,Z¹ is CH or N, R¹⁰ is halo, and Ring D is a 5-7 membered cycloalkylmonocyclic ring.

In some embodiments, the variables are as depicted in the compounds ofTable 1.

One embodiment provides the compounds of Table 1 shown below.

TABLE 1

I-1

I-2

I-3

I-4

I-5

I-6

I-7

I-8

I-9

I-10

I-11

I-12

I-13

I-14

I-15

I-16

I-17

I-18

I-19

I-20

I-21

I-22

I-23

Compounds of this invention include those described generally above, andare further illustrated by the classes, subclasses, and speciesdisclosed herein. As used herein, the following definitions shall applyunless otherwise indicated. For purposes of this invention, the chemicalelements are identified in accordance with the Periodic Table of theElements, CAS version, Handbook of Chemistry and Physics, 75^(th) Ed.Additionally, general principles of organic chemistry are described in“Organic Chemistry”, Thomas Sorrell, University Science Books,Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5^(th) Ed.,Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, theentire contents of which are hereby incorporated by reference.

As described herein, a specified number range of atoms includes anyinteger therein. For example, a group having from 1-4 atoms could have1, 2, 3, or 4 atoms.

As described herein, compounds of the invention may optionally besubstituted with one or more substituents, such as are illustratedgenerally above, or as exemplified by particular classes, subclasses,and species of the invention. It will be appreciated that the phrase“optionally substituted” is used interchangeably with the phrase“substituted or unsubstituted.” In general, the term “substituted”,whether preceded by the term “optionally” or not, refers to thereplacement of hydrogen radicals in a given structure with the radicalof a specified substituent. Unless otherwise indicated, an optionallysubstituted group may have a substituent at each substitutable positionof the group, and when more than one position in any given structure maybe substituted with more than one substituent selected from a specifiedgroup, the substituent may be either the same or different at everyposition. Combinations of substituents envisioned by this invention arepreferably those that result in the formation of stable or chemicallyfeasible compounds.

The term “stable”, as used herein, refers to compounds that are notsubstantially altered when subjected to conditions to allow for theirproduction, detection, recovery, purification, and use for one or moreof the purposes disclosed herein. In some embodiments, a stable compoundor chemically feasible compound is one that is not substantially alteredwhen kept at a temperature of 40° C. or less, in the absence of moistureor other chemically reactive conditions, for at least a week.

The term “aliphatic” or “aliphatic group”, as used herein, means astraight-chain (i.e., unbranched) branched or unbranched, substituted orunsubstituted hydrocarbon chain that is completely saturated or thatcontains one or more units of unsaturation that has a single point ofattachment to the rest of the molecule. Unless otherwise specified,aliphatic groups contain 1-20 aliphatic carbon atoms. In someembodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. Inother embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms.In still other embodiments, aliphatic groups contain 1-6 aliphaticcarbon atoms, and in yet other embodiments aliphatic groups contain 1-4aliphatic carbon atoms. Suitable aliphatic groups include, but are notlimited to, linear or branched, substituted or unsubstituted alkyl,alkenyl, or alkynyl groups. Specific examples include, but are notlimited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, vinyl,n-butenyl, ethynyl, and tert-butyl.

The term “alkyl” as used herein, means a straight-chain (i.e.,unbranched), branched or unbranched, substituted or unsubstituted,hydrocarbon chain that is completely saturated and has a single point ofattachment to the rest of the molecule. Unless otherwise specified,alkyl groups contain 1-6 alkyl carbon atoms. In some embodiments, alkylgroups contain 1-4 alkyl carbon atoms. In other embodiments, alkylgroups contain 1-3 alkyl carbon atoms. Examples include, but are notlimited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, n-butyl, andn-pentyl.

The term “cycloaliphatic” (or “carbocycle” or “carbocyclyl” or“cycloalkyl”) refers to a monocyclic C₃-C₈ hydrocarbon or bicyclicC₈-C₁₂ hydrocarbon that is completely saturated or that contains one ormore units of unsaturation, but which is not aromatic, that has a singlepoint of attachment to the rest of the molecule wherein any individualring in said bicyclic ring system has 3-7 members. Suitablecycloaliphatic groups include, but are not limited to, cycloalkyl andcycloalkenyl groups. Specific examples include, but are not limited to,cyclohexyl, cyclopropenyl, and cyclobutyl.

The term “heterocycle”, “heterocyclyl”, or “heterocyclic” as used hereinmeans non-aromatic, monocyclic, bicyclic, or tricyclic ring systems inwhich one or more ring members are an independently selected heteroatom.In some embodiments, the “heterocycle”, “heterocyclyl”, or“heterocyclic” group has three to fourteen ring members in which one ormore ring members is a heteroatom independently selected from oxygen,sulfur, nitrogen, or phosphorus, and each ring in the system contains 3to 7 ring members.

Suitable heterocycles include, but are not limited to,3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one,2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl,3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino,2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl,2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl,2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl,2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl,4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl,3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl,4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl,5-imidazolidinyl, indolinyl, tetrahydroquinolinyl,tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and1,3-dihydro-imidazol-2-one.

Cyclic groups, (e.g. cycloaliphatic and heterocycles), can be linearlyfused, bridged, or spirocyclic.

The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, orphosphorus, (including, any oxidized form of nitrogen, sulfur, orphosphorus; the quaternized form of any basic nitrogen or; asubstitutable nitrogen of a heterocyclic ring, for example N (as in3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as inN-substituted pyrrolidinyl)).

The term “unsaturated”, as used herein, means that a moiety has one ormore units of unsaturation.

The term “alkoxy”, or “thioalkyl”, as used herein, refers to an alkylgroup, as previously defined, attached to the principal carbon chainthrough an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom.

The terms “haloalkyl”, “haloalkenyl”, “haloaliphatic”, and “haloalkoxy”mean alkyl, alkenyl or alkoxy, as the case may be, substituted with oneor more halogen atoms. The terms “halogen”, “halo”, and “hal” mean F,Cl, Br, or I.

The term “aryl” used alone or as part of a larger moiety as in“aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic,bicyclic, and tricyclic ring systems having a total of five to fourteenring members, wherein at least one ring in the system is aromatic andwherein each ring in the system contains 3 to 7 ring members. The term“aryl” may be used interchangeably with the term “aryl ring”. The term“aryl” also refers to heteroaryl ring systems as defined hereinbelow.

The term “heteroaryl”, used alone or as part of a larger moiety as in“heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic,or tricyclic ring systems having a total of five to fourteen ringmembers, wherein at least one ring in the system is aromatic, at leastone ring in the system contains one or more heteroatoms, and whereineach ring in the system contains 3 to 7 ring members. The term“heteroaryl” may be used interchangeably with the term “heteroaryl ring”or the term “heteroaromatic”. Suitable heteroaryl rings include, but arenot limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl,4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl,5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl,2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl,4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl),2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl),triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl,benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), pyrazolyl (e.g.,2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl,1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl,1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyl,1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl,4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolinyl,3-isoquinolinyl, or 4-isoquinolinyl).

The term “protecting group” and “protective group” as used herein, areinterchangeable and refer to an agent used to temporarily block one ormore desired reactive sites in a multifunctional compound. In certainembodiments, a protecting group has one or more, or preferably all, ofthe following characteristics: a) is added selectively to a functionalgroup in good yield to give a protected substrate that is b) stable toreactions occurring at one or more of the other reactive sites; and c)is selectively removable in good yield by reagents that do not attackthe regenerated, deprotected functional group. Exemplary protectinggroups are detailed in Greene, T. W., Wuts, P. G in “Protective Groupsin Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999(and other editions of the book), the entire contents of which arehereby incorporated by reference. The term “nitrogen protecting group”,as used herein, refers to an agents used to temporarily block one ormore desired nitrogen reactive sites in a multifunctional compound.Preferred nitrogen protecting groups also possess the characteristicsexemplified above, and certain exemplary nitrogen protecting groups arealso detailed in Chapter 7 in Greene, T. W., Wuts, P. G in “ProtectiveGroups in Organic Synthesis”, Third Edition, John Wiley & Sons, NewYork: 1999, the entire contents of which are hereby incorporated byreference.

In some embodiments, an alkyl or aliphatic chain can be optionallyreplaced with another atom or group. Examples of such atoms or groupswould include, but are not limited to, —NR—, —O—, —S—, —CO₂—, —OC(O)—,—C(O)CO—, —C(O)—, —C(O)NR—, —C(═N—CN), —NRCO—, —NRC(O)O—, —SO₂NR—,—NRSO₂—, —NRC(O)NR—, —OC(O)NR—, —NRSO₂NR—, —SO—, or —SO₂—, wherein R isdefined herein.

Unless otherwise specified, the optional replacements form a chemicallystable compound. Optional replacements can occur both within the chainand at either end of the chain; i.e. both at the point of attachmentand/or also at the terminal end. Two optional replacements can also beadjacent to each other within a chain so long as it results in achemically stable compound. The optional replacements can alsocompletely replace all of the carbon atoms in a chain. For example, a C₃aliphatic can be optionally interrupted or replaced by —NR—, —C(O)—, and—NR— to form —NRC(O)NR— (a urea).

Unless otherwise specified, if the replacement occurs at the terminalend, the replacement atom is bound to an H on the terminal end. Forexample, if —CH₂CH₂CH₃ were optionally replaced with —O—, the resultingcompound could be —OCH₂CH₂, —CH₂OCH₃, or —CH₂CH₂OH.

Unless otherwise indicated, structures depicted herein are also meant toinclude all isomeric (e.g., enantiomeric, diastereomeric, and geometric(or conformational)) forms of the structure; for example, the R and Sconfigurations for each asymmetric center, (Z) and (E) double bondisomers, and (Z) and (E) conformational isomers. Therefore, singlestereochemical isomers as well as enantiomeric, diastereomeric, andgeometric (or conformational) mixtures of the present compounds arewithin the scope of the invention.

Unless otherwise indicated, all tautomeric forms of the compounds of theinvention are within the scope of the invention.

Unless otherwise indicated, a substituent can freely rotate around anyrotatable bonds. For example, a substituent drawn as

also represents

Additionally, unless otherwise indicated, structures depicted herein arealso meant to include compounds that differ only in the presence of oneor more isotopically enriched atoms. For example, compounds having thepresent structures except for the replacement of hydrogen by deuteriumor tritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enrichedcarbon are within the scope of this invention. Such compounds areuseful, for example, as analytical tools or probes in biological assays.

It will also be appreciated that the compounds of the present inventioncan exist in free form for treatment, or where appropriate, as apharmaceutically acceptable salt, salts, or mixtures thereof.

As used herein, the term “pharmaceutically acceptable salt” refers tosalts of a compound which are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of humans andlower animals without undue toxicity, irritation, allergic response andthe like, and are commensurate with a reasonable benefit/risk ratio.

Pharmaceutically acceptable salts are well known in the art. Forexample, S. M. Berge et al., describe pharmaceutically acceptable saltsin detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporatedherein by reference. Pharmaceutically acceptable salts of the compoundsof this invention include those derived from suitable inorganic andorganic acids and bases. These salts can be prepared in situ during thefinal isolation and purification of the compounds. Acid addition saltscan be prepared by 1) reacting the purified compound in its free-basedform with a suitable organic or inorganic acid and 2) isolating the saltthus formed.

Examples of pharmaceutically acceptable, nontoxic acid addition saltsare salts of an amino group formed with inorganic acids such ashydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid andperchloric acid or with organic acids such as acetic acid, oxalic acid,maleic acid, tartaric acid, citric acid, succinic acid or malonic acidor by using other methods used in the art such as ion exchange. Otherpharmaceutically acceptable salts include adipate, alginate, ascorbate,aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate,camphorate, camphorsulfonate, citrate, cyclopentanepropionate,digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate,glucoheptonate, glycerophosphate, glycolate, gluconate, hemisulfate,heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate,lactobionate, lactate, laurate, lauryl sulfate, malate, maleate,malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,oleate, oxalate, palmitate, palmoate, pectinate, persulfate,3-phenylpropionate, phosphate, picrate, pivalate, propionate,salicylate, stearate, succinate, sulfate, tartrate, thiocyanate,p-toluenesulfonate, undecanoate, valerate salts, and the like. Saltsderived from appropriate bases include alkali metal, alkaline earthmetal, ammonium and N⁺(C₁₋₄alkyl)₄ salts. This invention also envisionsthe quaternization of any basic nitrogen-containing groups of thecompounds disclosed herein. Water or oil-soluble or dispersible productsmay be obtained by such quaternization.

Base addition salts can be prepared by 1) reacting the purified compoundin its acid form with a suitable organic or inorganic base and 2)isolating the salt thus formed. Base addition salts include alkali oralkaline earth metal salts. Representative alkali or alkaline earthmetal salts include sodium, lithium, potassium, calcium, magnesium, andthe like. Further pharmaceutically acceptable salts include, whenappropriate, nontoxic ammonium, quaternary ammonium, and amine cationsformed using counterions such as halide, hydroxide, carboxylate,sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.Other acids and bases, while not in themselves pharmaceuticallyacceptable, may be employed in the preparation of salts useful asintermediates in obtaining the compounds of the invention and theirpharmaceutically acceptable acid or base addition salts.

The following abbreviations are used:

-   DCM dichloromethane-   EtOAc ethyl acetate-   DMSO dimethyl sulfoxide-   ATP adenosine triphosphate-   DTT dithiothreitol-   NMR nuclear magnetic resonance-   HPLC high performance liquid chromatography-   LCMS liquid chromatography-mass spectrometry-   TLC thin layer chromatography-   Rt retention time-   RT room temperature-   HEPES 4-(2-hydroxyethyl)-1-piperazine ethane-sulfonic acid-   FBS fetal bovine serum-   PVDF polyvinylidene fluoride-   PBST phosphate buffered saline with Tween 20-   TCF/LEF T cell factor/lymphoid enhancer factor-   DIPEA diisopropylethylamine

General Synthetic Methodology

The compounds of this invention may be prepared in general by methodssuch as those depicted in the general schemes below, and the preparativeexamples that follow. Unless otherwise indicated, all variables in thefollowing schemes are as defined herein.

Scheme 1 above shows a general synthetic route that is used forpreparing the compounds 5. Compounds of formula 5 can be prepared fromintermediate 1. The formation of amidine 2 is achieved by treatingnitrile derivative 1 with HCl in the presence of methanol and thentreating the intermediate imidate with NH₃ in ethanol. Intermediate 2 isthen treated with the corresponding beta-ketoester reflux in EtOH. Thecorresponding hydroxypyrimidine intermediate is treated with POCl₃ toyield chloroderivative 4. This reaction is amenable to a variety ofamidines 2. The chloropyrimidine 4 is treated with diverse amines likeNH₂Ht in the presence of DIPEA and NaI to yield the final compound 5.This reaction is also amenable to a variety of heterocyclic amines likeNH₂Ht.

Scheme 2 above shows a general synthetic route that is used forpreparing the compounds of formula 9. Compounds of formula 9 can beprepared from intermediate 7. The formation of intermediate 7 isachieved by reacting diethyl malonate with the corresponding amidine 2in the presence of EtONa as a base in refluxing ethanol. The crude isthen treated with POCl₃ to yield dichloropyrimidine intermediate 7. Thedichloropyrimidine intermediate is sequentially treated withheterocyclic amines and other substituted amine derivatives to yieldfinal compounds 9. These two reactions sequence are amenable to avariety of heterocyclic amines and a variety of substituted amines.

In Scheme II above, NRR′, R and R′, together with the nitrogen atom towhich they are attached, form an optionally substituted 5-6 memberedheterocyclic ring containing 1-2 heteroatoms selected from O, N, or S.

The present invention provides compounds and compositions that areuseful as inhibitors of protein kinases. In some embodiments, theprotein kinases are GSK-3 kinases.

As inhibitors of protein kinases, the compounds and compositions of thisinvention are particularly useful for treating or lessening the severityof a disease, condition, or disorder where a protein kinase isimplicated in the disease, condition, or disorder. In one aspect, thepresent invention provides a method for treating or lessening theseverity of a disease, condition, or disorder where a protein kinase isimplicated in the disease state. In another aspect, the presentinvention provides a method for treating or lessening the severity of adisease, condition, or disorder where inhibition of enzymatic activityis implicated in the treatment of the disease. In another aspect, thisinvention provides a method for treating or lessening the severity of adisease, condition, or disorder with compounds that inhibit enzymaticactivity by binding to the protein kinase. Another aspect provides amethod for treating or lessening the severity of a kinase disease,condition, or disorder by inhibiting enzymatic activity of the kinasewith a protein kinase inhibitor.

In some embodiments, said protein kinase inhibitor is a GSK-3 inhibitor.

As inhibitors of protein kinases, the compounds and compositions of thisinvention are also useful in biological samples. One aspect of theinvention relates to inhibiting protein kinase activity in a biologicalsample, which method comprises contacting said biological sample with acompound of formula I or a composition comprising said compound. Theterm “biological sample”, as used herein, means an in vitro or an exvivo sample, including, without limitation, cell cultures or extractsthereof; biopsied material obtained from a mammal or extracts thereof;and blood, saliva, urine, feces, semen, tears, or other body fluids orextracts thereof. The term “biological sample” does not refer to in vivosamples.

Inhibition of protein kinase activity in a biological sample is usefulfor a variety of purposes that are known to one of skill in the art.Examples of such purposes include, but are not limited to, bloodtransfusion, organ-transplantation, and biological specimen storage.

Another aspect of this invention relates to the study of protein kinasesin biological and pathological phenomena; the study of intracellularsignal transduction pathways mediated by such protein kinases; and thecomparative evaluation of new protein kinase inhibitors. Examples ofsuch uses include, but are not limited to, biological assays such asenzyme assays and cell-based assays.

The activity of the compounds as protein kinase inhibitors may beassayed in vitro, in vivo or in a cell line. In vitro assays includeassays that determine inhibition of either the kinase activity or ATPaseactivity of the activated kinase. Alternate in vitro assays quantitatethe ability of the inhibitor to bind to the protein kinase and may bemeasured either by radiolabelling the inhibitor prior to binding,isolating the inhibitor/kinase complex and determining the amount ofradiolabel bound, or by running a competition experiment where newinhibitors are incubated with the kinase bound to known radioligands.

Inhibition of GSK-3 activity has been linked to stem cell proliferation,cell differentiation, neuronal plasticity, and angiogenesis. Thesevarious functions are implicated in repair and regeneration. Inhibitorsof GSK-3 have been shown to sustain self-renewal of embryonic stemcells, promote neuron, beta-cell, myeloid and osteoblastdifferentiation. (Sato et al, Nature Medicine 10, 55-63, 2004; Ding etal PNAS 100, 7632-37, 2003; Branco et al J Cell Science 117, 5731-37,2004; Trowbridge et al, Nature Medicine 12, 89-98, 2006; Mussmann et al,JBC (Epub ahead of print) 2007; Kulkarni et al Journal of Bone andMineral Res. 21, 910-920, 2006) With respect to neuronal plasticity,inhibition of GSK-3 has been shown to be important for regulatingpolarity, long-term potentiation (LTP) and neurite/axon growth (Hooperet al European J of Neuroscience 25, 81-86, 2007; Kim et al, Neuron 52,981-996, 2006; Jiang et al Cell 120, 123-135, 2005). Inhibition of GSK-3also has been shown to induce angiogenesis in endothelial cells (Skurket al, Circulation Research 96, 308-318, 2005).

Accordingly, one aspect of this invention provides compounds that areuseful in cell repair and regeneration. In some embodiments, saidcompounds are used to promote cell proliferation, cell differentiation,neuronal plasticity, or angiogenesis. In some embodiments, saidcompounds are chemomodulators of cell differentiation. In otherembodiments, said compounds are chemomodulators of repair andregeneration.

In some embodiments, the compounds are used in increasing axonal anddendritic branching in neuronal cells. In some embodiments, thecompounds are used to promote neuroplasticity. In other embodiments, thecompounds are used to promote angiogenesis. In yet other embodiments,the compounds are used to promote neurogenesis. In yet otherembodiments, the compounds are used to treat neuropsychiatric disorders,such as mania and depression.

Another embodiment provides compounds that are used to treat diabetes bypromoting beta cell regeneration.

Yet another embodiment provides compounds that are used to treatosteoporosis by osteoblastogenesis.

GSK-3 functions as both a tyrosine and a serine/threonine kinase,similar to the DYRK kinase family. Like the DYRK kinase family, GSK-3auto-phosphorylates a key tyrosine residue in its kinase domain (GSK-3a,Tyr 279 and GSK-3b, Tyr 216). This tyrosine phosphorylation has beenshown to be important for positively modulating kinase activity. Locheadet al, demonstrated that this autophosphorylation occursintramolecularly at a post-translationally intermediate step prior tomaturation and is chaperones-dependent (Lochhead et al, Molecular Cell24, (2006), pp. 627-633). After maturation, GSK-3 loses its tyrosinekinase activity and acts exclusively as a serine and threonine kinasetowards exogenous substrates.

β-catenin is one of the exogenous serine/threonine substrates that GSK-3phosphorylates. Inhibition of β-catenin phosphorylation leads to anincrease in b-catenin levels that in turn translocate to the nucleus andtranscriptionally control many genes involved in cellular response andfunction. One potential safety concern for GSK-3 inhibitors is that useof the inhibitors could lead to hyperproliferation via β-catenininduction. As primarily a serine/threonine kinase GSK-3 is central tomany signaling pathways that control multiple cellular activities suchas proliferation, differentiation and metabolism.

Accordingly, one aspect of this invention provides compounds that canpartially attenuate GSK-3 activity without completely blocking theenzyme and affecting multiple substrates such as β-catenin. Oneembodiment provides compounds that selectively inhibit the tyrosineautophosphorylation form of the enzyme over the serine/threonine kinaseform.

In some embodiments, said enzyme is GSK-3α; in other embodiments,GSK-3β. In some embodiments, said compounds that have a β-catenin:GSK-3βwindow of at least 4 fold and up to 400 fold. In some embodiments, thecompounds have a β-catenin:GSK-3β window of at least 30 fold. In otherembodiments, said compounds have a β-catenin:GSK-3α window of at least35 fold and up to 600 fold.

Surprisingly, compounds that selectively inhibit theauto-phosphorylation of the tyrosine form of the GSK-3 enzyme relativeto the serine/threonine kinase form promote neuron growth and dendriteformation, such as by increasing axonal and dendritic branching inneuronal cells. Increasing neuron growth and dendrite formation isadvantageous and provides and unexpected and improved therapeuticefficacy when treating many types of degenerative conditions such asStroke, Post stroke, Spinal Cord Injury, Traumatic Brain Injury,Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, AmyotrophicLateral Sclerosis, Diabetic Neuropathy, Charcot-Marie-Tooth,Leukocytopenia, Diabetes and Osteoporosis.

Compounds that selectively inhibit the auto-phosphorylation of thetyrosine form of the GSK-3 enzyme relative to the serine/threoninekinase form also promote angiogenesis, which is advantageous andprovides an unexpected and improved therapeutic efficacy when treatingmany types of degenerative conditions such as the ones listed herein.

Another aspect provides compounds that are useful for the treatment ofdiseases, disorders, and conditions including, but not limited to,autoimmune diseases, inflammatory diseases, proliferative andhyperproliferative diseases, immunologically-mediated diseases,immunodeficiency disorders, immunomodulatory or immunosuppressivedisorder, bone diseases, metabolic diseases, neurological andneurodegenerative diseases, neurotrophic factor, cardiovasculardiseases, hormone related diseases, diabetes, allergies, asthma, andAlzheimer's disease. Another aspect of this invention provides compoundsthat are inhibitors of protein kinases, and thus are useful for thetreatment of the diseases, disorders, and conditions, along with otheruses described herein.

Another aspect provides pharmaceutically acceptable compositionscomprising any of the compounds described herein and optionallycomprising a pharmaceutically acceptable carrier, adjuvant or vehicle.In certain embodiments, these compositions optionally further compriseone or more additional therapeutic agents.

One aspect of this invention provides a method for the treatment orlessening the severity of a disease, disorder, or condition selectedfrom an autoimmune disease, an inflammatory disease, a proliferative orhyperproliferative disease, such as cancer, an immunologically-mediateddisease, an immunodeficiency disorders, a bone disease, a metabolicdisease, a neurological or neurodegenerative disease, a cardiovasculardisease, allergies, diabetes, asthma, Alzheimer's disease, or a hormonerelated disease, comprising administering an effective amount of acompound, or a pharmaceutically acceptable composition comprising acompound, to a subject in need thereof.

The term “cancer” includes, but is not limited to, the followingcancers: epidermoid Oral: buccal cavity, lip, tongue, mouth, pharynx;Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma,liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung:bronchogenic carcinoma (squamous cell or epidermoid, undifferentiatedsmall cell, undifferentiated large cell, adenocarcinoma), alveolar(bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma,chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus(squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma,lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas(ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoidtumors, vipoma), small bowel or small intestines (adenocarcinoma,lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma,lipoma, neurofibroma, fibroma), large bowel or large intestines(adenocarcinoma, tubular adenoma, villous adenoma, hamartoma,leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinarytract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma,leukemia), bladder and urethra (squamous cell carcinoma, transitionalcell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma),testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma,choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma,fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma(hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma,angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages;Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibroushistiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma(reticulum cell sarcoma), multiple myeloma, malignant giant cell tumorchordoma, osteochronfroma (osteocartilaginous exostoses), benignchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma andgiant cell tumors; Nervous system: skull (osteoma, hemangioma,granuloma, xanthoma, osteitis deformans), meninges (meningioma,meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma,glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform,oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological:uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumorcervical dysplasia), ovaries (ovarian carcinoma [serouscystadenocarcinoma, mucinous cystadenocarcinoma, unclassifiedcarcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors,dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma,intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma),vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma(embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast;Hematologic: blood (myeloid leukemia [acute and chronic], acutelymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferativediseases, multiple myeloma, myelodysplastic syndrome), Hodgkin'sdisease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell;lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma,squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, molesdysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis,Thyroid gland: papillary thyroid carcinoma, follicular thyroidcarcinoma; medullary thyroid carcinoma, undifferentiated thyroid cancer,multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma;and Adrenal glands: neuroblastoma. Thus, the term “cancerous cell” asprovided herein, includes a cell afflicted by any one of theabove-identified conditions. In some embodiments, the cancer is selectedfrom colorectal, thyroid, or breast cancer. In certain embodiments, an“effective amount” of the compound or pharmaceutically acceptablecomposition is that amount effective in order to treat said disease. Thecompounds and compositions, according to the method of the presentinvention, may be administered using any amount and any route ofadministration effective for treating or lessening the severity of saiddisease. In some embodiments, said disease is chosen from allergic ortype I hypersensitivity reactions, asthma, diabetes, Alzheimer'sdisease, Huntington's disease, Parkinson's disease, AIDS-associateddementia, bipolar disorder, amyotrophic lateral sclerosis (ALS, LouGehrig's disease), multiple sclerosis (MS), schizophrenia,leukocytopenia, cardiomyocyte hypertrophy, reperfusion/ischemia, stroke,baldness, transplant rejection, graft versus host disease, rheumatoidarthritis, and solid and hematologic malignancies. In some embodiments,said disease is chosen from diabetes, bipolar disorder, schizophrenia,stroke, Huntington's disease, leukocytopenia and cardiomyocytehypertrophy.

In other embodiments of this invention, said disease is a protein-kinasemediated condition. In some embodiments, said protein kinase in GSK-3.

The term “protein kinase-mediated condition”, as used herein means anydisease or other deleterious condition in which a protein kinase plays arole. Such conditions include, without limitation, autoimmune diseases,inflammatory diseases, proliferative and hyperproliferative diseases,immunologically-mediated diseases, immunodeficiency disorders,immunomodulatory or immunosuppressive disorder, bone diseases, metabolicdiseases, neurological and neurodegenerative diseases, cardiovasculardiseases, hormone related diseases, diabetes, allergies, asthma, andAlzheimer's disease.

The term “GSK-3-mediated condition”, as used herein means any disease orother deleterious condition in which GSK-3 plays a role. Such conditionsinclude, without limitation, diabetes, diabetic neuropathy,osteoporosis, Alzheimer's disease, Huntington's disease, Parkinson'sdisease, AIDS-associated dementia, bipolar disorder, amyotrophic lateralsclerosis (ALS, Lou Gehrig's disease), multiple sclerosis (MS),schizophrenia, leukocytopenia, cardiomyocyte hypertrophy, stroke, spinalcord injury, traumatic brain injury, Charcot-Marie-Tooth, and rheumatoidarthritis.

In some embodiments, said disease is a degenerative condition. In someembodiments, said degenerative condition is chosen from stroke,Alzheimer's Disease, Parkinson's Disease, Huntington's Disease,Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis (MS), spinalcord injury, traumatic brain injury, Charcot-Marie-Tooth,leukocytopenia, diabetes, diabetic neuropathy, and osteoporosis.

In some embodiments, said disease is a neurodegenerative condition. Inanother embodiment, said neurodegenerative conditions is selected fromstroke, Alzheimer's disease, Parkinson's disease, Huntington's disease,Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis (MS), spinalcord injury, traumatic brain injury, and Charcot-Marie-Tooth.

One embodiment provides a method increasing axonal and dendriticbranching in neuronal cells comprising the step of contacting said cellswith a compound described herein. Another embodiment provides a methodof promoting neuroplasticity comprising the step of contacting saidcells with a compound described herein. Another embodiment provides amethod of promoting angiogenesis comprising the step of contacting saidcells with a compound described herein. Yet another embodiment providesa method of treating neuropsychiatric disorders, such as mania anddepression, comprising administering to a patient a compound describedherein.

According to one aspect of the invention, said neurodegenerative diseaseis stroke. In some embodiments, the compounds are used to treat strokepatients during stroke recovery. In some cases, the compounds are usedin post-stroke administration. The length of treatment can range from 1month to one year. In some embodiments, the compound is administeredafter the stroke has occurred. In some embodiments, said administrationoccurs immediately after ischemia. In other embodiments, saidadministration occurs 48 hours after ischemia to 6 months afterischemia. In some embodiments, the compounds are used in combinationwith other forms of stroke recovery treatment, such as physical therapy.

Another embodiment provides a method of treating diabetes comprising thestep of contacting a beta cell with a compound described herein. In someembodiments, the compound promotes beta cell regeneration.

Another embodiment provides a method of treating osteoporosis comprisingthe step of contacting a bone cell with a compound described herein. Insome embodiments, said compound promotes osteoblastogenesis in the cell.

It will also be appreciated that certain of the compounds of presentinvention can exist in free form for treatment, or where appropriate, asa pharmaceutically acceptable salt or pharmaceutically acceptablederivative thereof.

It should be understood that this invention includesmixtures/combinations of different pharmaceutically acceptable salts andalso mixtures/combinations of compounds in free form andpharmaceutically acceptable salts.

As described herein, the pharmaceutically acceptable compositions of thepresent invention additionally comprise a pharmaceutically acceptablecarrier, adjuvant, or vehicle, which, as used herein, includes any andall solvents, diluents, or other liquid vehicle, dispersion orsuspension aids, surface active agents, isotonic agents, thickening oremulsifying agents, preservatives, solid binders, lubricants and thelike, as suited to the particular dosage form desired. Remington'sPharmaceutical Sciences, Sixteenth Edition, E. W. Martin (MackPublishing Co., Easton, Pa., 1980) discloses various carriers used informulating pharmaceutically acceptable compositions and knowntechniques for the preparation thereof. Except insofar as anyconventional carrier medium is incompatible with the compounds of theinvention, such as by producing any undesirable biological effect orotherwise interacting in a deleterious manner with any othercomponent(s) of the pharmaceutically acceptable composition, its use iscontemplated to be within the scope of this invention.

Some examples of materials which can serve as pharmaceuticallyacceptable carriers include, but are not limited to, ion exchangers,alumina, aluminum stearate, lecithin, serum proteins, such as humanserum albumin, buffer substances such as phosphates, glycine, sorbicacid, or potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes, such as protaminesulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, wool fat, sugars such aslactose, glucose and sucrose; starches such as corn starch and potatostarch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth;malt; gelatin; talc; excipients such as cocoa butter and suppositorywaxes; oils such as peanut oil, cottonseed oil; safflower oil; sesameoil; olive oil; corn oil and soybean oil; glycols; such a propyleneglycol or polyethylene glycol; esters such as ethyl oleate and ethyllaurate; agar; buffering agents such as magnesium hydroxide and aluminumhydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'ssolution; ethyl alcohol, and phosphate buffer solutions, as well asother non-toxic compatible lubricants such as sodium lauryl sulfate andmagnesium stearate, as well as coloring agents, releasing agents,coating agents, sweetening, flavoring and perfuming agents,preservatives and antioxidants can also be present in the composition,according to the judgment of the formulator.

The protein kinase inhibitors or pharmaceutical salts thereof may beformulated into pharmaceutical compositions for administration toanimals or humans. These pharmaceutical compositions, which comprise anamount of the protein inhibitor effective to treat or prevent a proteinkinase-mediated condition and a pharmaceutically acceptable carrier, areanother embodiment of the present invention. In some embodiments, saidprotein kinase-mediated condition is a GSK-3-mediated condition. In someembodiments, a GSK-3-mediated condition.

The exact amount of compound required for treatment will vary fromsubject to subject, depending on the species, age, and general conditionof the subject, the severity of the infection, the particular agent, itsmode of administration, and the like. The compounds of the invention arepreferably formulated in dosage unit form for ease of administration anduniformity of dosage. The expression “dosage unit form” as used hereinrefers to a physically discrete unit of agent appropriate for thepatient to be treated. It will be understood, however, that the totaldaily usage of the compounds and compositions of the present inventionwill be decided by the attending physician within the scope of soundmedical judgment. The specific effective dose level for any particularpatient or organism will depend upon a variety of factors including thedisorder being treated and the severity of the disorder; the activity ofthe specific compound employed; the specific composition employed; theage, body weight, general health, sex and diet of the patient; the timeof administration, route of administration, and rate of excretion of thespecific compound employed; the duration of the treatment; drugs used incombination or coincidental with the specific compound employed, andlike factors well known in the medical arts. The term “patient”, as usedherein, means an animal, preferably a mammal, and most preferably ahuman.

The pharmaceutically acceptable compositions of this invention can beadministered to humans and other animals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments, or drops), bucally, as an oral or nasal spray, orthe like, depending on the severity of the infection being treated. Incertain embodiments, the compounds of the invention may be administeredorally or parenterally at dosage levels of about 0.01 mg/kg to about 50mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subjectbody weight per day, one or more times a day, to obtain the desiredtherapeutic effect.

Liquid dosage forms for oral administration include, but are not limitedto, pharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups and elixirs. In addition to the active compounds,the liquid dosage forms may contain inert diluents commonly used in theart such as, for example, water or other solvents, solubilizing agentsand emulsifiers such as ethyl alcohol, isopropyl alcohol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butylene glycol, dimethylformamide, oils (in particular,cottonseed, groundnut, corn, germ, olive, castor, and sesame oils),glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fattyacid esters of sorbitan, and mixtures thereof. Besides inert diluents,the oral compositions can also include adjuvants such as wetting agents,emulsifying and suspending agents, sweetening, flavoring, and perfumingagents.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions may be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectablesolution, suspension or emulsion in a nontoxic parenterally acceptablediluent or solvent, for example, as a solution in 1,3-butanediol. Amongthe acceptable vehicles and solvents that may be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

In order to prolong the effect of a compound of the present invention,it is often desirable to slow the absorption of the compound fromsubcutaneous or intramuscular injection. This may be accomplished by theuse of a liquid suspension of crystalline or amorphous material withpoor water solubility. The rate of absorption of the compound thendepends upon its rate of dissolution that, in turn, may depend uponcrystal size and crystalline form. Alternatively, delayed absorption ofa parenterally administered compound form is accomplished by dissolvingor suspending the compound in an oil vehicle. Injectable depot forms aremade by forming microencapsule matrices of the compound in biodegradablepolymers such as polylactide-polyglycolide. Depending upon the ratio ofcompound to polymer and the nature of the particular polymer employed,the rate of compound release can be controlled. Examples of otherbiodegradable polymers include poly(orthoesters) and poly(anhydrides).Depot injectable formulations are also prepared by entrapping thecompound in liposomes or microemulsions that are compatible with bodytissues.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating excipients or carriers such ascocoa butter, polyethylene glycol or a suppository wax which are solidat ambient temperature but liquid at body temperature and therefore meltin the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activecompound is mixed with at least one inert, pharmaceutically acceptableexcipient or carrier such as sodium citrate or dicalcium phosphateand/or a) fillers or extenders such as starches, lactose, sucrose,glucose, mannitol, and silicic acid, b) binders such as, for example,carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia, c) humectants such as glycerol, d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate, e) solutionretarding agents such as paraffin, f) absorption accelerators such asquaternary ammonium compounds, g) wetting agents such as, for example,cetyl alcohol and glycerol monostearate, h) absorbents such as kaolinand bentonite clay, and i) lubricants such as talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof. In the case of capsules, tablets and pills, thedosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using such excipients as lactoseor milk sugar as well as high molecular weight polyethylene glycols andthe like. The solid dosage forms of tablets, dragees, capsules, pills,and granules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They may optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions that can be usedinclude polymeric substances and waxes. Solid compositions of a similartype may also be employed as fillers in soft and hard-filled gelatincapsules using such excipients as lactose or milk sugar as well as highmolecular weight polethylene glycols and the like.

The active compounds can also be in microencapsulated form with one ormore excipients as noted above. The solid dosage forms of tablets,dragees, capsules, pills, and granules can be prepared with coatings andshells such as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active compound may be admixed with at least one inertdiluent such as sucrose, lactose or starch. Such dosage forms may alsocomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets and pills, the dosage forms may also comprisebuffering agents. They may optionally contain opacifying agents and canalso be of a composition that they release the active ingredient(s)only, or preferentially, in a certain part of the intestinal tract,optionally, in a delayed manner. Examples of embedding compositions thatcan be used include polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. The active componentis admixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives or buffers as may be required.Ophthalmic formulation, eardrops, and eye drops are also contemplated asbeing within the scope of this invention. Additionally, the presentinvention contemplates the use of transdermal patches, which have theadded advantage of providing controlled delivery of a compound to thebody. Such dosage forms can be made by dissolving or dispensing thecompound in the proper medium. Absorption enhancers can also be used toincrease the flux of the compound across the skin. The rate can becontrolled by either providing a rate controlling membrane or bydispersing the compound in a polymer matrix or gel.

In addition to the compounds of this invention, pharmaceuticallyacceptable derivatives or prodrugs of the compounds of this inventionmay also be employed in compositions to treat or prevent theabove-identified disorders.

A “pharmaceutically acceptable derivative or prodrug” means anypharmaceutically acceptable ester, salt of an ester or other derivativeof a compound of this invention which, upon administration to arecipient, is capable of providing, either directly or indirectly, acompound of this invention or an inhibitorily active metabolite orresidue thereof. Particularly favoured derivatives or prodrugs are thosethat increase the bioavailability of the compounds of this inventionwhen such compounds are administered to a patient (e.g., by allowing anorally administered compound to be more readily absorbed into the blood)or which enhance delivery of the parent compound to a biologicalcompartment (e.g., the brain or lymphatic system) relative to the parentspecies.

Pharmaceutically acceptable prodrugs of the compounds of this inventioninclude, without limitation, esters, amino acid esters, phosphateesters, metal salts and sulfonate esters.

Pharmaceutically acceptable carriers that may be used in thesepharmaceutical compositions include, but are not limited to, ionexchangers, alumina, aluminum stearate, lecithin, serum proteins, suchas human serum albumin, buffer substances such as phosphates, glycine,sorbic acid, potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes, such as protaminesulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol,sodium carboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol andwool fat.

The compositions of the present invention may be administered orally,parenterally, by inhalation spray, topically, rectally, nasally,buccally, vaginally or via an implanted reservoir. The term “parenteral”as used herein includes, but is not limited to, subcutaneous,intravenous, intramuscular, intra-articular, intra-synovial,intrasternal, intrathecal, intrahepatic, intralesional and intracranialinjection or infusion techniques. Preferably, the compositions areadministered orally, intraperitoneally or intravenously.

Sterile injectable forms of the compositions of this invention may beaqueous or oleaginous suspension. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectable preparationmay also be a sterile injectable solution or suspension in a non-toxicparenterally-acceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilmay be employed including synthetic mono- or di-glycerides. Fatty acids,such as oleic acid and its glyceride derivatives are useful in thepreparation of injectables, as are natural pharmaceutically-acceptableoils, such as olive oil or castor oil, especially in theirpolyoxyethylated versions. These oil solutions or suspensions may alsocontain a long-chain alcohol diluent or dispersant, such ascarboxymethyl cellulose or similar dispersing agents which are commonlyused in the formulation of pharmaceutically acceptable dosage formsincluding emulsions and suspensions. Other commonly used surfactants,such as Tweens, Spans and other emulsifying agents or bioavailabilityenhancers which are commonly used in the manufacture of pharmaceuticallyacceptable solid, liquid, or other dosage forms may also be used for thepurposes of formulation.

The pharmaceutical compositions of this invention may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, aqueous suspensions or solutions. In thecase of tablets for oral use, carriers commonly used include, but arenot limited to, lactose and corn starch. Lubricating agents, such asmagnesium stearate, are also typically added. For oral administration ina capsule form, useful diluents include lactose and dried cornstarch.When aqueous suspensions are required for oral use, the activeingredient is combined with emulsifying and suspending agents. Ifdesired, certain sweetening, flavoring or coloring agents may also beadded.

Alternatively, the pharmaceutical compositions of this invention may beadministered in the form of suppositories for rectal administration.These can be prepared by mixing the agent with a suitable non-irritatingexcipient which is solid at room temperature but liquid at rectaltemperature and therefore will melt in the rectum to release the drug.Such materials include, but are not limited to, cocoa butter, beeswaxand polyethylene glycols.

The pharmaceutical compositions of this invention may also beadministered topically, especially when the target of treatment includesareas or organs readily accessible by topical application, includingdiseases of the eye, the skin, or the lower intestinal tract. Suitabletopical formulations are readily prepared for each of these areas ororgans.

Topical application for the lower intestinal tract can be effected in arectal suppository formulation (see above) or in a suitable enemaformulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may beformulated in a suitable ointment containing the active componentsuspended or dissolved in one or more carriers. Carriers for topicaladministration of the compounds of this invention include, but are notlimited to, mineral oil, liquid petrolatum, white petrolatum, propyleneglycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax andwater. Alternatively, the pharmaceutical compositions can be formulatedin a suitable lotion or cream containing the active components suspendedor dissolved in one or more pharmaceutically acceptable carriers.Suitable carriers include, but are not limited to, mineral oil, sorbitanmonostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated asmicronized suspensions in isotonic, pH adjusted sterile saline, or,preferably, as solutions in isotonic, pH adjusted sterile saline, eitherwith or without a preservative such as benzylalkonium chloride.Alternatively, for ophthalmic uses, the pharmaceutical compositions maybe formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also beadministered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well-known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

The amount of protein kinase inhibitor that may be combined with thecarrier materials to produce a single dosage form will vary dependingupon the host treated, the particular mode of administration.Preferably, the compositions should be formulated so that a dosage ofbetween 0.01-100 mg/kg body weight/day of the inhibitor can beadministered to a patient receiving these compositions.

It should also be understood that a specific dosage and treatmentregimen for any particular patient will depend upon a variety offactors, including the activity of the specific compound employed, theage, body weight, general health, sex, diet, time of administration,rate of excretion, drug combination, and the judgment of the treatingphysician and the severity of the particular disease being treated. Theamount of inhibitor will also depend upon the particular compound in thecomposition.

According to another embodiment, the invention provides methods fortreating or preventing a protein kinase-mediated condition (in someembodiments, a GSK-3-mediated condition) comprising the step ofadministering to a patient one of the above-described pharmaceuticalcompositions. The term “patient”, as used herein, means an animal,preferably a human.

Preferably, that method is used to treat or prevent a condition selectedfrom cancers such as cancers of the breast, colon, prostate, skin,pancreas, brain, genitourinary tract, lymphatic system, stomach, larynxand lung, including lung adenocarcinoma and small cell lung cancer;stroke, diabetes, myeloma, hepatomegaly, cardiomegaly, Alzheimer'sdisease, Parkinson's Disease, Huntington's Disease, Amyotrophic LateralSclerosis (ALS), multiple sclerosis (MS), spinal cord injury, traumaticbrain injury, Charcot-Marie-Tooth, leukocytopenia, diabetic neuropathy,osteoporosis, cystic fibrosis, and viral disease, or any specificdisease described above.

Another aspect of the invention relates to inhibiting protein kinaseactivity in a patient, which method comprises administering to thepatient a compound of formula I or a composition comprising saidcompound.

Depending upon the particular protein kinase-mediated conditions to betreated or prevented, additional drugs, which are normally administeredto treat or prevent that condition, may be administered together withthe inhibitors of this invention. For example, chemotherapeutic agentsor other anti-proliferative agents may be combined with the proteinkinase inhibitors of this invention to treat proliferative diseases.

Those additional agents may be administered separately, as part of amultiple dosage regimen, from the protein kinase inhibitor-containingcompound or composition. Alternatively, those agents may be part of asingle dosage form, mixed together with the protein kinase inhibitor ina single composition.

In some embodiments, said protein kinase inhibitor is a GSK-3 kinaseinhibitor.

This invention may also be used in methods other than those involvingadministration to a patient.

The compounds of this invention may be prepared in general by methodsknown to those skilled in the art. Those compounds may be analyzed byknown methods, including but not limited to LCMS (liquid chromatographymass spectrometry) and NMR (nuclear magnetic resonance). Compounds ofthis invention may be also tested according to these examples. It shouldbe understood that the specific conditions shown below are onlyexamples, and are not meant to limit the scope of the conditions thatcan be used for making, analyzing, or testing the compounds of thisinvention. Instead, this invention also includes conditions known tothose skilled in that art for making, analyzing, and testing thecompounds of this invention.

EXAMPLES

As used herein, the term “Rt (min)” refers to either HPLC or LCMSretention time, in minutes, associated with the compound.

Unless otherwise indicated, the HPLC method utilized to obtain thereported retention time is as follows:

-   -   Column: ACE C8 column, 4.6×150 mm    -   Gradient: 0-100% acetonitrile+methanol 60:40 (20 mM Tris        phosphate)    -   Flow rate: 1.5 mL/minute    -   Detection: 225 nm.

LCMS (Liquid Chromatography Mass Spectrometry) samples were analyzed ona MicroMass Quattro Micro mass spectrometer operated in single MS modewith electrospray ionization. Samples were introduced into the massspectrometer using chromatography. Mobile phase for all mass spec.analysis consisted of acetonitrile-water mixtures with either 0.2%formic acid or 0.1% TFA as a modifier. Column gradient conditions are10%-90% acetonitrile over 3 mins gradient time and 5 mins run time on aWaters YMC Pro-C18 4.6×50 mm column. Flow rate is 1.5 ml/min.

¹H-NMR spectra were recorded at 400 MHz using a Bruker DPX 400instrument. The following compounds of formula I were prepared andanalyzed as follows.

Intermediate 1

cyclohexanecarboximidamide hydrochloride

The temperature of a mixture of cyclohexane carbonitrile (60 g, 550mmol, 1 eq) in Et₂O (150 ml) and MeOH (33 ml) was lowered to 0° C.before HCl (g) was bubbled through for 20 min. The reaction mixture wasthen removed to the fridge O/N. The resulting white solid was suspendedin Et2O and filtered to give the methyl cyclohexanecarbimidateintermediate (125.1 g, 128%). This crude solid was suspended in amixture of EtOH (400 ml)/2M NH₃ in EtOH (100 ml) at 0° C. before NH3 (g)was bubbled through the suspension for 2 h. The reaction mixture wasthen placed in the fridge O/N. The resulting solid was filtered andwashed with MeOH to yield a filtrate which was then concentratedin-vacuo. The residue was taken up in MeOH and concentrated in-vacuountil a solid began to precipitate at which time Et2O was added. Theresulting solid then formed was filtered to give a sticky solid that wasplaced into the vac-oven O/N to yield the desired product as a whitesolid (87.80 g, 98%). 1H (400 MHz, DMSO) 1.00-1.88 (10H, m), 2.35-2.57(1H, m), 8.86-9.02 (3H, m).

Intermediate 2

2-cyclohexyl-5,6-dimethylpyrimidin-4-ol

A solution of sodium ethoxide (previously prepared by dissolving sodium(6.36 g, 278 mmol, 3 eq) in EtOH (300 ml)), stirring at RT, was treatedwith ethyl 2-methyl-3-oxobutanoate (16.94 ml, 120 mmol, 1.3 eq). Aslurry of cyclohexanecarboximidamide hydrochloride (15 g, 92 mmol, 1 eq)in EtOH (100 ml) was then added and the RM heated at reflux for 8 h. TheRM was concentrated, water added and the pH adjusted to ˜7-8 with 2NHCl. Following acidification a white solid precipitated and this wasfiltered and dried in the vac-oven to yield2-cyclohexyl-5,6-dimethylpyrimidin-4-ol as a white solid (28.91 g,151%). 1H (400 MHz, DMSO) 1.03-1.86 (10H, m), 1.96 (3H, s), 2.16 (3H,s), 2.36-2.57 (1H, m), 12.05 (1H, brs); ES+207.

Intermediate 3

4-chloro-2-cyclohexyl-5,6-dimethylpyrimidine

POCl₃ (220 ml, 2.4 mol, ˜26 eq) was cooled to ˜−50° C. before beingcarefully treated with 2-cyclohexyl-5,6-dimethylpyrimidin-4-ol (28.9 g,‘92 mmol’, 1 eq). The cooling bath was then removed and the pot allowedto warm to RT followed by heating to reflux for 6 h. The RM wasconcentrated, treated with ice and saturated NaHCO₃ and extracted intoEt2O before being dried (sodium sulfate)/concentrated. The resulting oilwas subjected to column chromatography using EtOAc (10%): 40-60 Petrols(90%) as eluent to yield 4-chloro-2-cyclohexyl-5,6-dimethylpyrimidine asan oil (5.7011 g, 28% over first two steps). 1H (400 MHz, DMSO)1.16-1.90 (10H, m), 2.26 (3H, s), 2.46 (3H, s), 2.60-2.75 (1H, m).ES+225.

Intermediate 4

The overall synthetic scheme for the synthesis of5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine 5 is depicted below.

2-Chloro-5-fluoronicotinic acid (6)

To a round-bottomed flask under a N₂ atmosphere were added degassed DMF(270 mL), Pd(OAc)₂ (0.05 eq, 2.7 g, 11.9 mmol), PPh₃ (0.1 eq, 6.2 g,23.8 mmol), and degassed Et₃N (6 eq, 200 mL, 1428.6 mmol). The mixturewas stirred for 20 minutes, HCOOH (3 eq, 28 mL, 714.3 mmol) was thenadded. 5 minutes later, 2,6-dichloro-5-fluoronicotinic acid (50 g, 238.1mmol) was added. The mixture was stirred at 50° C. The reaction wasfollowed by analysis (1H NMR) of a worked-up aliquot. When all startingmaterial was consumed (24 h), the mixture was cooled to 0° C. and water(500 mL) was added. After 20 minutes, The mixture was filtered through apad of Celite that was rinsed with water. The mixture was basified to pH9 with 30% aq. NaOH and washed with EtOAc (2×). HCl (12 N) was addedslowly to pH 1 and the solution was saturated with NaCl. The mixture wasextracted with EtOAc (3×). The combined organic extracts were washedwith brine, dried (Na₂SO₄), and concentrated under reduced pressure togive 37 g (88%) of a beige solid used in the next step without furtherpurification.

¹H NMR (DMSO-d₆, 300 MHz): δ 8.16 (dd, 1H); 8.58 (d, 1H).

2-Chloro-5-fluoronicotinamide (3)

To a solution of 2-chloro-5-fluoronicotinic acid 6 (50 g, 285 mmol) andDMF (2 mL, 28 mmol) in DCM (400 mL) at 0° C. was added oxalyl chloride(64 mL, 741 mmol) dropwise. The reaction mixture was stirred at roomtemperature overnight and concentrated in vacuo. The resulting yellowliquid was dissolved in 1,4-dioxane (600 mL), cooled at 0° C. and NH₃(g) was bubbled through the solution for 30 minutes. The mixture wasstirred at room temperature overnight. The resulting mixture wasfiltered and the filtrate was concentrated to give compound 3 (44 g,89%) as a beige solid. ¹H NMR (DMSO-d₆, 300 MHz): δ 7.84 (s, 1H), 7.96(dd, 1H), 8.09 (s, 1H), 8.49 (d, 1H).

2-Chloro-5-fluoronicotinonitrile (4)

A suspension of crude compound 3 (65 g, 372.4 mmol) and Et3N (114 mL,819.2 mmol) in DCM (700 mL) was cooled to 0° C. and TFAA (57 mL, 409.6mmol) was added dropwise. The resulting yellow solution was stirred for90 minutes at 0° C., diluted with DCM, washed with sat. aq. NaHCO₃ andbrine, and dried (Na₂SO₄). The mixture was filtered and concentrated.Kugel Rohr distillation of the residue (˜70° C./1 mbar) gave 50 g (86%)of compound 4 as a beige solid.

Compound 4 can also be purified by column chromatography (SiO₂, 8:1heptane:EtOAc). ¹H NMR (CDCl₃, 300 MHz): δ 7.78 (dd, 1H); 8.49 (d, 1H).

5-Fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine (5)

To a solution of compound 4 (50 g, 321.7 mmol) in 1-butanol (1 L) wasadded hydrazine monohydrate (150 mL, 3.2 mol), and the mixture wasrefluxed for 4 h. The mixture was cooled to room temperature andconcentrated. The precipitate was successively washed on filter withwater (2×) and Et₂O (2×) and dried in vacuo overnight to give compound 5(44 g, 88%) as a yellow solid. ¹H NMR (DMSO-d₆, 300 MHz): δ 5.53 (s,2H); 7.94 (dd, 1H); 8.35 (dd, 1H); 12.02 (s, 1H).

Example 1 I-3

(N-(2-cyclohexyl-5,6-dimethylpyrimiidin-4-yl)-5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine

A solution of 4-chloro-2-cyclohexyl-5,6-dimethylpyrimidine (5.70 g, 25.4mmol, 1 eq) in NMP (50 ml), stirring at RT, was treated with5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine (4.63 g, 30.4 mmol, 1.2 eq).The RM was heated at 130° C. for 4 h before being cooled to RT. The RMwas diluted with EtOAc/water and the organics were washed with sNaHCO3and further water. During work up a solid was produced and this wasfiltered. Treatment of the solid with DCM/MeOH/40-60-petrols produced(N-(2-cyclohexyl-5,6-dimethylpyrimiidin-4-yl)-5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-aminewhich was isolated as a white solid. The solid was dried in a vac-oven @80° C. O/N to yield VRT-763633 (Lot2) as a white solid (5.2608 g, 61%)).1H (400 MHz, DMSO) 0.87-1.22 (5H, m), 1.40-1-62 (5H, m), 2.04 (3H, s),2.20 (3H, s), 2.25 (1H, quin), 7.67 (1H, dd), 8.40 (1H, dd), 8.91 (1H,s), 13.13 (1H, s). ES+341, ES−339.

The following compounds were made in a manner similar to the mannerdescribed above.

Compounds I-3 to I-10 and I-12 to I-21 were made according to methoddescribed in Scheme I and the method described for making Example 1.

Compounds I-1, I-2, I-11, and I-22 were made according to the methoddescribed in Scheme II.

Table 2 below describes analytical data associated with compounds shownin Table 1.

TABLE 2 M + 1 LCMS Cmpd # (obs) Rt (min) NMR I-1 347 3.92 (400 MHz,DMSO) 1.10-1.96 (10H, m), 2.56-2.69 (1H, m), 7.65 (1H, brs), 8.27-8.39(1H, m), 8.58 (1H, s), 10.72 (1H, s), 13.34 (1H, s). I-2 410 4.07 (400MHz, DMSO) 1.14-1.93 (10H, m), 2.19 (3H, s), 2.32-2.56 (5H, m),3.49-3.59 (4H, m), 7.00 (1H, brs), 7.18-7.30 (1H, m), 7.36-7.47 (1H, m),7.83-7.95 (1H, m), 9.63 (1H, s), 12.44 (1H, s). I-3 341.57 3.63 (DMSO)0.87-1.22 (5H, m), 1.40-1-62 (5H, m), 2.04 (3H, s), 2.20 (3H, s), 2.25(1H, quin), 7.67 (1H, dd), 8.40 (1H, dd), 8.91 (1H, s), 13.13 (1H, s).I-4 363 3.42 (400 MHz, DMSO) 1.77-2.14 (8H, m), 2.35 (3H, s), 2.75-2.87(1H, m), 7.41 (1H, brs), 8.26-8.38 (1H, m), 8.52-8.62 (1H, m), 10.22(1H, s), 13.22 (1H, s). I-5 343 2.98 (400 MHz, DMSO) 1.44-1.67 (4H, m),2.18 (3H, s), 2.35 (3H, s), 2.59-2.70 (1H, m), 3.22-3.37 (2H, m),3.71-3.82 (2H, m), 7.73-7.83 (1H, m), 8.52-8.59 (1H, m), 9.10 (1H, s),13.33 (1H, s). I-6 378 4.07 (400 MHz, DMSO) 1.64-1.80 (6H, m), 1.94-2.12(9H, m), 2.32 (3H, s), 7.19-7.55 (3H, m), 7.75-7.87 (1H, m), 9.81 (1H,s), 12.56 (1H, s). I-7 299 3.17 (400 MHz, DMSO) 1.74-1.86 (1H, m),1.91-2.05 (1H, m), 2.16-2.27 (2H, m), 2.30-2.43 (5H, m), 3.49-3.62 (1H,m), 7.38 (1H, brs), 8.30-8.41 (1H, m), 8.52-8.62 (1H, m), 10.24 (1H, s),13.20 (1H, s). I-8 341 3.73 (400 MHz, DMSO) 1.38-1.81 (10H, m),1.85-1.97 (1H, m), 2.33 (3H, s), 2.73-2.84 (1H, m), 7.25-7.41 (1H, m),8.29-8.38 (1H, m), 8.49-8.60 (1H, m), 10.11 (1H, s), 13.15 (1H, s). I-9313 3.32 (400 MHz, DMSO) 1.52-2.00 (8H, m), 2.33 (3H, s), 3.04-3.16 (1H,m), 7.36 (1H, brs), 8.25-8.41 (1H, m), 8.49-8.62 (1H, m), 10.17 (1H, s),13.19 (1H, s). I-10 327.4 1.72 H NMR (500 MHz, MeOD) 8.54 (s, 1 H), 8.22(s, 1H), 2.80 (m, 1H), 1.9-1.1 (m, 10H) I-11 397 4.02 (400 MHz, DMSO)1.12-1.94 (10H, m), 2.42-2.55 (1H, m), 3.46-3.55 (4H, m), 3.65-3.73 (4H,m), 7.00 (1H, brs), 7.18-7.29 (1H, m), 7.38-7.47 (1H, m), 7.85-7.93 (1H,m), 9.67 (1H, s), 12.44 (1H, s). I-12 284 3.19 (400 MHz. DMSO) 0.83-1.00(4H, m), 1.93-2.04 (1H, m), 7.18-7.34 (2H, m), 7.42-7.52 (1H, m),7.68-7.80 (1H, m), 9.86 (1H, s), 12.54 (1H, s). I-13 298 3.33 (400 MHz,DMSO) 1.75-1.87 (1H, m), 1.91-2.05 (1H, m), 2.16-2.26 (1H, m), 2.31-2.45(5H, m), 3.49-3.62 (1H, m), 7.19-7.53 (3H, m), 7.75-7.88 (1H, m), 10.02(1H, s), 12.57 (1H, s). I-14 312 3.48 (400 MHz, DMSO) 1.52-2.00 (8H, m),2.32 (3H, s), 3.03-3.15 (1H, m), 7.20-7.54 (3H, m), 7.72-7.87 (1H, m),9.96 (1H, s), 12.57 (1H, s). I-15 328 3.13 (400 MHz, DMSO) 1.80-1.97(4H, m), 2.39 (3H, s), 2.85-2.97 (1H, m), 3.36-3.54 (2H, m), 3.93-4.06(2H, m), 7.26-7.37 (1H, m), 7.41-7.59 (2H, m), 7.77-7.90 (1H, m), 10.06(1H, s), 12.65 (1H, s). I-16 355 3.75 (400 MHz, DMSO) 1.26-1.67 (10H,m), 1.71-1.83 (2H, m), 2.18 (3H, s), 2.34 (3H, s), 2.55-2.66 (1H, m),7.75-7.89 (1H, m), 8.50-8.59 (1H, m), 9.00-9.15 (1H, m), 13.26 (1H, s).I-17 329 2.87 (400 MHz., DMSO) 1.75-1.85 (4H, m), 2.35 (3H, s),2.79-2.91 (1H, m), 3.31-3.48 (2H, m), 3.87-3.97 (2H, m), 7.40 (1H, brs),8.24-8.39 (1H, m), 8.54-8.63 (1H, m), 10.21 (1H, s), 13.22 (1H, s). I-18341.4 1.79 H NMR (500 MHz, DMSO-d6) 13.73 (s, H), 8.64 (s, 1H), 8.25 (s,1H), 1.89-1.1 (m12, H), 0.85 (d, J = 7.9 Hz, 3H), 0.74 (d, J = 12.7 Hz,1H). I-19 379 4.01 (400 MHz, DMSO) 1.63-1.78 (6H, m), 1.84-2.06 (9H, m),2.34 (3H, s), 7.30 (1H, brs), 8.27-8.39 (1H, m), 8.52-8.62 (1H, m),10.03 (1H, s), 13.19 (1H, s). I-20 285 3.03 (400 MHz, DMSO) 0.88-0.98(4H, m), 1.94-2.04 (1H, m), 2.30 (3H, s), 7.30 (1H, s), 8.25-8.35 (1H,m), 8.54-8.62 (1H, m), 10.07 (1H, s), 13.17 (1H, s). I-21 371.58 3.76(DMSO) 1.20-1.39 (3H, m), 1.40 (6H, s), 1.50-1.61 (2H, m), 1.63-1.92(5H, m), 2.63 (1H, quin), 5.15 (1H, s, OH), 7.14 (1H, br s), 8.33 (1H,dd), 8.56 (1H, dd), 10.12 (1H, s), 13.18 (1H, s). I-22 346 4.02 (400MHz, DMSO) 1.12-1.96 (10H, m), 2.55-2.69 (1H, m), 7.22-7.32 (1H, m),7.44-7.92 (3H, m), 10.57 (1H, s), 12.70 (1H, s). I-23 326.4 1.94 H NMR(500 MHz, DMSO-d6) 13.12 (s, 1H), 11.58 (s, 1H), 7.68 (s, 1H), 7.58 (dd,J = 4.2, 8.9 Hz, 1H), 7.32 (t, J = 9.0 Hz, 1H), 2.80 (s, 1H), 1.92-1.05(m, 10H).

Example 2 GSK-3 Inhibition Assay

Compounds of the present invention were screened for their ability toinhibit GSK-3β (AA 1-420) activity using a standard coupled enzymesystem (Fox et al., Protein Sci. 1998, 7, 2249). Reactions were carriedout in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl₂, 25 mMNaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrateconcentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis,Mo.) and 300 μM peptide (American Peptide, Sunnyvale, Calif.). Reactionswere carried out at 30° C. and 20 nM GSK-3β. Final concentrations of thecomponents of the coupled enzyme system were 2.5 mM phosphoenolpyruvate,300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactatedehydrogenase.

An assay stock buffer solution was prepared containing all of thereagents listed above with the exception of ATP and the test compound ofthe present invention. The assay stock buffer solution (175 μl) wasincubated in a 96 well plate with 5 μl of the test compound of thepresent invention at final concentrations spanning 0.002 μM to 30 μM at30° C. for 10 min. Typically, a 12-point titration was conducted bypreparing serial dilutions (from 10 mM compound stocks) with DMSO of thetest compounds of the present invention in daughter plates. The reactionwas initiated by the addition of 20 μl of ATP (final concentration 20μM). Rates of reaction were obtained using a Molecular DevicesSpectramax plate reader (Sunnyvale, Calif.) over 10 min at 30° C. TheK_(i) values were determined from the rate data as a function ofinhibitor concentration. Compounds of the invention were found toinhibit GSK-3.

The following compounds were found to inhibit GSK-3 at a Ki value of <25nM: I-1, I-3, I-4, I-8 to I-10, I-14, I-16 to I-19, I-21 to I-23.

The following compounds were found to inhibit GSK-3 at a Ki value of<500 nM and ≧25 nM: I-2, I-5 to I-7, I-11 to I-13, I-15, and I-20.

Example 3 GSK-3α and GSK3β p-TYR Inhibition Assay

Compounds are screened for their ability to inhibit the phosphorylationof tyrosine (TYR) residues through the use of western blotting of Jurkatcells dosed with the compounds. The phosphorylation of the specific TYRresidues tested are GSK3α TYR 279 and GSK3β TYR 216.

Preparation of Cells and Lysates

Jurkat cells are seeded at a density of 2×10⁵ cells/well in a 12 welldish in starvation media (RPMI+1% FBS+P/S). Following starvation for 16hours, the compound is dosed into each well at a final DMSOconcentration of 0.3% and cells are incubated o/n at 37° C. 5% CO₂. Thenext day, cells are spun down at 1500 rpm, washed with PBS, and lysed in100 uL Laemli sample buffer with β-mercaptoethanol.

Western Blot Protocol

15 microliters (uL) of cell lysates are loaded onto a 10% tris-glycinegel and run at 120v for 2 hours or until dye front runs off of the gel.The protein is then transferred onto a PVDF membrane at 100v for 60 min.PBST (PBS containing 0.1% Tween 20, such as 1 ml Tween per 1 L of PBS)is then made up and used for all washes and antibody incubations. Theblot is blocked in 5% nonfat milk PBST for one hour.

The primary antibody (GSK-3α/β pTYR 279/216 at 1:1000 dilution Upstatecat#05-413) is then added in 5%-nonfat milk PBST overnight at 4° C. withgentle rocking. The blot is then washed in PBST for 5 min. This is thenrepeated 4 times. A secondary anti-mouse-HRP conjugated antibody (1:5000dilution) is added for 60 min in 5% milk PBST. The blot is then washedin PBST for 5 min. This is also repeated 4 times. 3.0 mL of thedeveloping solution (ECL plus Western Blotting Detection System fromAmersham/GE cat# RPN2132) is made and then added. The solution isswirled over the blot for ˜30 sec. The blot is then developed usingCL-Xposure clear blue X-ray film. GAPDH expression level is used as aloading control, (GAPDH antibody: santa cruz 25-778) at 1:10000dilution.

For determination of GSK-3α and GSK-3β pTYR IC50, the density of therespective bands for each protein at specific compound concentration iscompared to a no compound DMSO treated control cell sample present oneach exposure. IC50 numbers are defined as the concentration of compoundin which the density of the GSK-3α or GSK-3β band is 50% of the nocompound control.

Example 4 β-Catenin Stabilization Protocol

GSK-3 phosphorylation of β-catenin targets it to the proteosome fordegradation. Inhibition of GSK-3 results in accumulation of β-catenin inthe cytosol of cells which through interaction with the transcriptionfactor TCF/LEF translocates to the nucleus and drives the transcriptionof Wnt-dependent genes. The assay is designed to determine the level ofβ-catenin dependent TCF/LEF transcriptional activity in a quantitativemanner through the use of a β-lactamase reporter assay in Jurkat cellsdosed with a compound.

Jurkat β-catenin cells are starved overnight in assay media (1% FBS, 1×Penstrep, RPMI) in the flask. The next day Jurkat β-catenin cells areseeded in 96 well flat bottom plates at a density of 50,000 cells/wellin assay media in a volume of 100 ul. The compound is added to the wellat a final DMSO concentration of 0.75% and incubated at 37° C. o/n. Thenext day, 20 uL of 6×CCF4 dye is added to the wells and incubated atroom temperature for 1-2 hours. Plates are read on the Cytofluor 4000series multiwell plate reader and the 460/530 ratio is determined. TheGSK-3 IC50 for induction of β-catenin is determined by plotting the460/530 ratio against the concentration of compound (Log scale) andusing the equation of the slope to calculate the point at which theratio is 50% of the maximum effect.

β-catenin:GSK-3 windows were calculated by dividing the β-catenin IC50value obtained in Example 4 by the GSK-3α or GSK3β p-TYR IC50 valueobtained in Example 3.

The following compounds were found to have a β-catenin:GSK-3α windowsbetween 35 and 500 fold: I-4, I-5, I-15, I-17, and I-21. The followingcompounds were found to have a β-catenin:GSK-3α window between 500 and2000 fold: I-8 to I-10, I-16, I-19, and I-23. The following compoundswere found to have a β-catenin:GSK-3α window between 2000 and 6000: I-3and I-18.

The following compounds were found to have a β-catenin:GSK-3β windowbetween 4 and 25 fold: I-4, I-15, I-17, and I-18. The followingcompounds were found to have a β-catenin:GSK-3β window between 25 and100 fold: I-8 to I-10, I-16, I-21, and I-23. The following compoundswere found to have a β-catenin:GSK-3β window between 100 and 400 fold:I-3, I-5, and I-19.

Table 3 shows GSK-3α pTYR, GSK-3β pTYR, and β-catenin IC50 data forselect compounds of Table 1.

TABLE 3 GSK3a GSK3b Beta Compound pTYR 279: pTYR 216: Catenin NumberIC50: uM) IC50: (uM) IC50: (uM) I-3 0.0007 0.013 3.7 I-4 0.001 0.02 0.21I-5 0.03 0.8 >10 I-8 0.0003 0.01 0.6 I-9 0.002 0.048 1.4 I-10 0.00050.006 0.4 I-15 0.03 0.2 4.83 I-16 0.003 0.083 3.7 I-17 0.003 0.03 0.11I-18 0.001 0.3 2.4 I-19 0.002 0.02 3.32 I-21 0.003 0.02 1 I-23 0.0020.025 1.1

While we have described a number of embodiments of this invention, it isapparent that our basic examples may be altered to provide otherembodiments that utilize or encompass the compounds, methods, andprocesses of this invention. Therefore, it will be appreciated that thescope of this invention is to be defined by the appended claims.

We claim:
 1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein: Ht is

wherein any substitutable carbon on Ht is independently and optionallysubstituted with —R¹⁰; Ring D is a 3-10 membered heterocyclyl; wheresaid heterocyclyl contains 1-2 heteroatoms selected from O, N, or S; andwherein the heterocyclyl is independently and optionally substitutedwith 1-5-R⁵; Ring D is bonded to the pyrimidine via a carbon atom; Z¹ isN, CH, or CR¹⁰; R^(X) is H, halo, or C₁₋₆alkyl, wherein the alkyl isindependently and optionally substituted with 1-5 groups selected fromhalo, —CN, and —OR; R^(Y) is H, halo, C₂₋₆alkyl, or a 5-6 memberedheterocyclyl ring containing 1-2 heteroatoms selected from O, N, or S;wherein said R^(Y) is independently and optionally substituted with 1-4halo, CN, OR, or C₂₋₆alkyl; each R¹⁰ is independently selected fromC₁₋₆alkyl, haloC₁₋₆alkyl, halo, OR, C(═O)R, CO₂R, COCOR, NO₂, CN, S(O)R,SO₂R, SR, N(R⁴)₂, CON(R⁴)₂, SO₂N(R⁴)₂, OC(═O)R, N(R⁴)COR, or N(R⁴)CO₂R;each R⁴ is independently selected from H, C₁₋₆alkyl, or haloC₁₋₆alkyl;each R⁵ is independently selected from halo, haloC₁₋₆alkyl, orC₁₋₆alkyl; and each R is independently selected from H, C₁₋₆alkyl, orhaloC₁₋₆alkyl.
 2. The compound according to claim 1 wherein Ht is


3. The compound according to claim 2, wherein R¹⁰ is halo.
 4. Thecompound according to claim 3, wherein R¹⁰ is fluoro.
 5. (canceled) 6.The compound according to claim 1, wherein Z¹ is N.
 7. (canceled) 8.(canceled)
 9. (canceled)
 10. The compound according to claim 1, whereinR^(X) is H.
 11. The compound according to claim 1, wherein R^(X) ismethyl.
 12. The compound according to claim 4, wherein the halo isfluoro.
 13. The compound according to claim 1, wherein R^(Y) is halo orC₁₋₆ alkyl.
 14. The compound according to claim 13, wherein R^(Y) ismethyl.
 15. (canceled)
 16. (canceled)
 17. The compound according toclaim 1, wherein said heterocyclyl is morpholinyl, piperidinyl, orpiperazinyl.
 18. (canceled)
 19. (canceled)
 20. (canceled)
 21. (canceled)22. (canceled)
 23. (canceled)
 24. The compound according to claim 1,wherein Ring D is a 6-membered heterocyclyl containing one oxygen atom.25. (canceled)
 26. The compound of claim 1 selected from the following:


27. A composition comprising a compound according to any one of claim 1or 26, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.28-46. (canceled)